Efficacy of once-daily insulin

December 2009
Primary Care Reports;Dec2009 Pharmacology Watch Supp, p1
The article discusses a new study on the use of once-a-day insulin to treat type 2 diabetes. The study was conducted by researchers from England, involving 708 patient who had suboptimal hemoglobin A1c. It was found that the basal insulin group presented lesser hypoglycemic episodes as well as weight gain.


Related Articles

  • Case Study: A 64-Year-Old Man With a 9-Year History of Type 2 Diabetes in Whom Insulin Therapy Led to Improved Control But No Weight Gain After 6 Months. Thomas-Doberson, Deborah; Thomas-Dobersen, Deborah // Clinical Diabetes;Fall2003, Vol. 21 Issue 4, p190 

    Presents a case study of the impact of initiating insulin therapy on the body weight of a 64-year old white man with type 2 diabetes in the U.S. Medical history of the patient; Comparison of the weight gains of patients treated with insulin and chlorpropamide or glyburide; Correlations between...

  • Efficacy of once-daily insulin.  // Infectious Disease Alert;Dec2009 Pharmacology Watch Suppleme, p1 

    The article focuses on a study which examined the efficacy of a once-a-day insulin therapy in patients with type 2 diabetes. The study included 708 diabetic patients who were randomize to receive either twice a day of biphasic insulin aspart, three times a day of prandial insulin aspart or once...

  • Preserving beta-cell function in DM2.  // Neurology Alert;Aug2009 Clinical Briefs in, Vol. 14 Issue 8, p15 

    The article provides a comparison on the one-year treatment of patients suffering from metformin-treated type 2 diabetes with exenatide and treatment with insulin glargine to improve beta-cell function. It references a study by MC Bunck and others, published in the 2009 issue of "Diabetes Care."...

  • Adjunctive prandial or biphasic insulin for type 2 diabetes improved glycaemic control but increased hypoglycaemia and weight gain. Hollmand, R. R. // Evidence Based Medicine;Jun2008, Vol. 13 Issue 3, p77 

    STUDY DESIGN Design: randomised controlled trial (Treating to Target in Type 2 Diabetes [4-T]). Allocation: concealed. Blinding: unblinded. STUDY QUESTION Setting: 58 centres in Ireland and the UK. Patients: 708 patients ⩾18 years of age (mean age 62 y, 64% men) who had type 2 diabetes for...

  • Intensive Insulin Therapy in Type 2 Diabetes (T2D) Patients Previously Treated with Glargine Plus Oral Agents: Prandial NPL/Lispro Mixtures vs Glargine/Lispro Basal/Bolus. Rosenstock, Julio; Ahmann, Andrew J.; Colon, Gildred; Scism-Bacon, Jamie L.; Jiang, Honghua H.; Martin, Sherry // Diabetes;Jun2007 Supplement 1, Vol. 56, pA51 

    We report the first head-to-head comparison of intensive insulin therapies (intensive mixtures therapy [IMT] vs basal bolus therapy [BBT]) in T2D patients previously treated with glargine (≥30 U/d) + oral agents. Patients with A1C ≥ 7.5 and ≤ 12% were randomized to IMT (lispro...

  • Early Insulin Treatment in Type 2 Diabetes. Meneghini, Luigi F. // Diabetes Care;Nov2009 Supplement, Vol. 32, pS266 

    The article focuses on the early introduction of insulin therapy in newly diagnosed patients with type 2 diabetes. The potential physiological effects of insulin replacement treatment is discussed. It notes that aggressive and frequently utilization of insulin treatment at disease onset in type...

  • Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes. Lingvay, Ildiko; Legendre, Jaime L.; Kaloyanova, Polina F.; Zhang, Song; Adams-Huet, Beverley; Raskin, Philip // Diabetes Care;Oct2009, Vol. 32 Issue 10, p1789 

    OBJECTIVE -- Early use of insulin after diagnosis of type 2 diabetes is met with resistance because of associated weight gain, hypoglycemia, and fear of decreased compliance and quality of life (QoL). RESEARCH DESIGN AND METHODS-- In treatment-naive patients with newly diagnosed type 2 diabetes,...

  • Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes. Diamant, Michaela; Nauck, Michael A.; Shaginian, Rimma; Malone, James K.; Cleall, Simon; Reaney, Matthew; de Vries, Danielle; Hoogwerf, Byron J.; MacConell, Leigh; Wolffenbuttel, Bruce H. R. // Diabetes Care;Oct2014, Vol. 37 Issue 10, p2763 

    OBJECTIVE Mealtime insulin is commonly added to manage hyperglycemia in type 2 diabetes when basal insulin is insufficient. However, this complex regimen is associated with weight gain and hypoglycemia. This study compared the efficacy and safety of exenatide twice daily or mealtime insulin...

  • Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes. Riddle, Matthew; Pencek, Richard; Charenkavanich, Supoat; Lutz, Karen; Wilhelm, Ken; Porter, Lisa // Diabetes Care;Sep2009, Vol. 32 Issue 9, p1577 

    OBJECTIVE -- To compare the efficacy and safety of adding mealtime pramlintide or rapid-acting insulin analogs (RAIAs) to basal insulin for patients with inadequately controlled type 2 diabetes. RESEARCH DESIGN AND METHODS -- In a 24-week open-label, multicenter study, 113 patients were randomly...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics